Lipella Pharmaceuticals Inc. (LIPO)

Every figure this model derived for LIPO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-09-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 2,156,317 CashAndCashEquivalentsAtCarryingValue 2025-09-30
current assets 2,079,288 AssetsCurrent 2025-09-30
current liabilities 642,399 LiabilitiesCurrent 2025-09-30
equity 1,487,595 StockholdersEquity 2025-09-30
interest expense 11,263 InterestPaidNet 2025-09-30
ocf -4,775,734 NetCashProvidedByUsedInOperatingActivities 2025-09-30
revenue 389,783 Revenues 2025-09-30

The ratios

The figures themselves rather than their scores — what somebody looking up LIPO on one particular measure came for.

RatioValue
cash operating margin-1387.2
current ratio3.24
current ratio reported3.24
dilution pct39.59
fcf margin-1225.23
growth cv1.63
interest cover-480.33
operating margin-1387.94
owner earnings margin-1225.23
revenue growth-19.39
revenue growth per share-42.25
rule of 40-1407.33
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about LIPO's figures. Written by the derivation as it ran, not added afterwards.